Sana Biotechnology Inc (SANA)

NASDAQ
Currency in USD
2.76
-0.05(-1.78%)
Closed·
After Hours
2.83+0.07(+2.54%)
·
SANA Scorecard
Full Analysis
Quickly burning through cash
SANA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.702.97
52 wk Range
1.267.40
Key Statistics
Edit
Prev. Close
2.81
Open
2.8
Day's Range
2.7-2.97
52 wk Range
1.26-7.4
Volume
3.52M
Average Vol. (3m)
3.73M
1-Year Change
-51.41%
Book Value / Share
0.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SANA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.33
Upside
+238.16%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Sana Biotechnology Inc News & Analysis

Show more

Sana Biotechnology Inc Company Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin’s lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam’s proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology Inc SWOT Analysis


Financial Outlook
Analysts project a cash runway into 2026, with price targets around $5.00. Learn how Sana's future value hinges on clinical success and market penetration.
Market Differentiation
Delve into how Sana's unique hypoimmune platform could set it apart in the competitive cell therapy landscape, offering off-the-shelf products without immunosuppression.
Pipeline Progress
Explore Sana's strategic focus on T1D and AID programs, with promising results from UP421 and anticipated data releases for SC291 and SC262 in 2025.
Hypoimmune Platform
Sana's innovative technology aims to produce immune-evading cells, potentially revolutionizing treatments for Type 1 Diabetes and autoimmune diseases.
Read full SWOT analysis

Compare SANA to Peers and Sector

Metrics to compare
SANA
Peers
Sector
Relationship
P/E Ratio
−3.0x−4.1x−0.5x
PEG Ratio
−0.070.000.00
Price / Book
3.0x2.5x2.6x
Price / LTM Sales
-1,682.3x3.0x
Upside (Analyst Target)
215.8%217.7%51.5%
Fair Value Upside
Unlock35.8%9.4%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 9.33
(+238.16% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.21 / -0.24
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SANA Income Statement

People Also Watch

7.000
NVTS
+2.04%
3.710
LAES
-1.33%
1.750
QSI
+4.17%
15.710
QBTS
+1.03%

FAQ

What Is the Sana Biotechnology (SANA) Stock Price Today?

The Sana Biotechnology stock price today is 2.76

What Stock Exchange Does Sana Biotechnology Trade On?

Sana Biotechnology is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Sana Biotechnology?

The stock symbol for Sana Biotechnology is "SANA."

What Is the Sana Biotechnology Market Cap?

As of today, Sana Biotechnology market cap is 622.53M.

What Is Sana Biotechnology's Earnings Per Share (TTM)?

The Sana Biotechnology EPS (TTM) is -0.88.

When Is the Next Sana Biotechnology Earnings Date?

Sana Biotechnology will release its next earnings report on Jul 31, 2025.

From a Technical Analysis Perspective, Is SANA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Sana Biotechnology Stock Split?

Sana Biotechnology has split 0 times.

How Many Employees Does Sana Biotechnology Have?

Sana Biotechnology has 194 employees.

What is the current trading status of Sana Biotechnology (SANA)?

As of Jun 19, 2025, Sana Biotechnology (SANA) is trading at a price of 2.76, with a previous close of 2.81. The stock has fluctuated within a day range of 2.70 to 2.97, while its 52-week range spans from 1.26 to 7.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.